Growth Hormone Deficiency (GHD)
11
2
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
9.1%
1 terminated out of 11 trials
80.0%
-6.5% vs benchmark
45%
5 trials in Phase 3/4
75%
3 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency
GB06 Phase III Trial for Pediatric Growth Hormone Deficiency
REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)
Hypothalamic-Stratified Nursing Pathway for Pediatric Craniopharyngioma
Development of a Personalized Growth Hormone Treatment Profile (PGTP) Report for Pediatric Endocrinology
Evaluating the Efficacy and Safety of GB08 Injection in Pediatric Patients With Growth Hormone Deficiency
Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency
Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
Treatment of Children With Insufficient Secretion of Growth Hormone